These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31110735)

  • 21. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Vu K; Ai W
    Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab Vedotin in CD30+ Lymphomas.
    Perini GF; Pro B
    Biol Ther; 2013; 3(1):15-23. PubMed ID: 24392301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
    Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
    J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP
    Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast Implant-Associated Anaplastic Large Cell Lymphoma.
    Rastogi P; Deva AK; Prince HM
    Curr Hematol Malig Rep; 2018 Dec; 13(6):516-524. PubMed ID: 30345474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules.
    Clemens MW; Nava MB; Rocco N; Miranda RN
    Gland Surg; 2017 Apr; 6(2):169-184. PubMed ID: 28497021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
    Sasapu A; Dunn ALJ; Gardner J; Wong HK
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
    Premji S; Barbieri A; Roth C; Rohren EM; Rivero G; Teegavarapu SP
    Case Rep Hematol; 2022; 2022():4700787. PubMed ID: 35721802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaplastic large T-cell lymphoma and breast implants: a review of the literature.
    Jewell M; Spear SL; Largent J; Oefelein MG; Adams WP
    Plast Reconstr Surg; 2011 Sep; 128(3):651-661. PubMed ID: 21865998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease.
    Evans MG; Medeiros LJ; Marques-Piubelli ML; Wang HY; Ortiz-Hidalgo C; Pina-Oviedo S; Morine A; Clemens MW; Hunt KK; Iyer S; Hu Q; Recavarren C; Demichelis R; Romero M; Sohani AR; Misialek M; Amin MB; Bueso-Ramos CE; Carballo-Zarate AA; Lee HJ; Ok CY; Xu J; Miranda RN
    Mod Pathol; 2021 Dec; 34(12):2148-2153. PubMed ID: 34155351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.